The association between the human leukocyte antigen (HLA) complex and Meniere disease has been explored, but results have varied among different populations worldwide.
We report 2 cases of HLA-B27-associated Meniere disease, and we describe their clinical and immunocytologic features as determined by the patients' serum reactions with mouse inner ears.
In order to examine the immunocytologic features of the proposed association between HLA-B27 and Meniere disease, we devised a protocol involving the fluorescence-labeled reaction of human serum with mouse inner ear sections.
These results suggest that a humoral immune response--specifically an antigen-antibody reaction--may underlie the development of Meniere disease symptomatology in carriers of HLA-B27.
We have described the cases of 2 patients with signs and symptoms of autoimmune Meniere disease who were found to be HLA-B27 carriers.
Yet a group from Spain reported no association between Meniere disease and HLA-A, -B, -C, or -DR alleles.
Intratympanic streptomycin therapy for the vertigo spells of Meniere disease was first described by Schuknecht in 1957.
In the last 10 years, intratympanic gentamicin has been used extensively to treat the intractable vertigo of unilateral Meniere disease.
This study was undertaken to compare results and efficacy of gentamicin-injection therapy for Meniere disease using subjective and objective end points for duration of therapy.
All patients in this study had unilateral Meniere disease, as described by the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck Surgery, (5) and intractable vertigo.
Also, the natural fluctuations in hearing that accompany Meniere disease must be considered.
A small percentage of patients in each group had hearing loss after treatment, but the significance of this result is difficult to assess because of the natural fluctuations in hearing with Meniere disease.